Thioredoxin and cancer: A role for thioredoxin in all states of tumor oxygenation

Cancers

Volumn 2, Issue 2, 2010, Pages 209-232

  Karlenius, Therese Christina ^a   Tonissen, Kathryn Fay ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Cycling hypoxia; Hypoxia; Oxidative stress; Preconditioning; Thioredoxin; Tumor

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; AURANOFIN; CISPLATIN; CURCUMIN; DOCETAXEL; DOXORUBICIN; GADOLINIUM TEXAPHYRIN; HYDROGEN PEROXIDE; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID HYDROPEROXIDE; OXYGEN; PEROXIREDOXIN; REACTIVE OXYGEN METABOLITE; REDOX EFFECTOR FACTOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TAMOXIFEN; THIOCTIC ACID; THIOREDOXIN; THIOREDOXIN REDUCTASE 1; THIOREDOXIN REDUCTASE 2; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR MAF; TRANSCRIPTION FACTOR NRF2;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL DEATH; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); COLON CANCER; ENZYME BINDING; ENZYME INACTIVATION; HEART PROTECTION; HUMAN; HYPOXIA; ISCHEMIC PRECONDITIONING; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; NONHUMAN; OVARY CANCER; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; OXYGEN TRANSPORT; PROMYELOCYTIC LEUKEMIA; PROTEIN BINDING; PROTEIN EXPRESSION; REOXYGENATION; REVIEW; STOMACH CANCER; TEA; TISSUE OXYGENATION; TUMOR CELL; TUMOR OXYGENATION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UPREGULATION;

EID: 79952270060     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2020209     Document Type: Review

References (150)

1. Nauseef, W.M. The NADPH-dependent oxidase of phagocytes. Proc. Assoc. Am. Physicians 1999, 111, 373-382.
2. Kuppusamy, P.; Zweier, J.L. Characterization of free radical generation by xanthine oxidase. Evidence for hydroxyl radical generation. J. Biol. Chem. 1989, 264, 9880-9884.
3. Cadenas, E.; Davies, K.J. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic. Biol. Med. 2000, 29, 222-230.
4. Fridovich, I. Fundamental aspects of reactive oxygen species, or what's the matter with oxygen? Ann. N Y Acad. Sci. 1999, 893, 13-18.
5. Finkel, T.; Holbrook, N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408, 239-247.
6. Finkel, T. Oxygen radicals and signaling. Curr. Opin. Cell Biol. 1998, 10, 248-253.
7. Thannickal, V.J.; Fanburg, B.L. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell Mol. Physiol. 2000, 279, L1005-1028.
8. Kang, D.H. Oxidative stress, DNA damage, and breast cancer. AACN Clin. Issues 2002, 13, 540-549.
9. Michiels, C.; Minet, E.; Mottet, D.; Raes, M. Regulation of gene expression by oxygen: NF-kappaB and HIF-1, two extremes. Free Radic. Biol. Med. 2002, 33, 1231-1242.
10. Nordberg, J.; Arner, E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 2001, 31, 1287-1312.
11. Wasserman, W.W.; Fahl, W.E. Functional antioxidant responsive elements. Proc. Natl. Acad. Sci. USA 1997, 94, 5361-5366.
12. Ishii, T.; Itoh, K.; Takahashi, S.; Sato, H.; Yanagawa, T.; Katoh, Y.; Bannai, S.; Yamamoto, M. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J. Biol. Chem. 2000, 275, 16023-16029.
13. Katoh, Y.; Iida, K.; Kang, M. I.; Kobayashi, A.; Mizukami, M.; Tong, K. I.; McMahon, M.; Hayes, J.D.; Itoh, K.; Yamamoto, M. Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. Arch. Biochem. Biophys. 2005, 433, 342-350.
14. Lee, J.M.; Johnson, J.A. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J. Biochem. Mol. Biol. 2004, 37, 139-143.
15. Rocha, S. Gene regulation under low oxygen: holding your breath for transcription. Trends. Biochem. Sci. 2007, 32, 389-397.
16. Pouyssegur, J.; Dayan, F.; Mazure, N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441, 437-443.
17. Keith, B.; Simon, M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129, 465-472.
18. Matsui, M.; Oshima, M.; Oshima, H.; Takaku, K.; Maruyama, T.; Yodoi, J.; Taketo, M.M. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev. Biol. 1996, 178, 179-185.
19. A. Thioredoxin. Annu. Rev. Biochem. 1985, 54, 237-271.
20. Arner, E.S.; Holmgren, A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 2000, 267, 6102-6109.
21. Gromer, S.; Urig, S.; Becker, K. The thioredoxin system--from science to clinic. Med. Res. Rev. 2004, 24, 40-89.
22. Nishinaka, Y.; Nakamura, H.; Masutani, H.; Yodoi, J. Redox control of cellular function by thioredoxin; a new therapeutic direction in host defence. Arch. Immunol. Ther. Exp. (Warsz) 2001, 49, 285-292.
23. Powis, G.; Montfort, W.R. Properties and biological activities of thioredoxins. Annu. Rev. Biophys. Biomol. Struct. 2001, 30, 421-455.
24. Nakamura, H.; Nakamura, K.; Yodoi, J. Redox regulation of cellular activation. Annu. Rev. Immunol. 1997, 15, 351-369.
25. Taniguchi, Y.; Taniguchi-Ueda, Y.; Mori, K.; Yodoi, J. A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (Trx) gene. Nucleic Acids Res. 1996, 24, 2746-2752.
26. Spyrou, G.; Enmark, E.; Miranda-Vizuete, A.; Gustafsson, J. Cloning and expression of a novel mammalian thioredoxin. J. Biol. Chem. 1997, 272, 2936-2941.
27. Miranda-Vizuete, A.; Ljung, J.; Damdimopoulos, A.E.; Gustafsson, J.A.; Oko, R.; Pelto-Huikko, M.; Spyrou, G. Characterization of Sptrx, a novel member of the thioredoxin family specifically expressed in human spermatozoa. J. Biol. Chem. 2001, 276, 31567-31574.
28. Sun, Q.A.; Su, D.; Novoselov, S.V.; Carlson, B.A.; Hatfield, D.L.; Gladyshev, V.N. Reaction mechanism and regulation of mammalian thioredoxin/glutathione reductase. Biochemistry 2005, 44, 14528-14537.
29. Mitsui, A.; Hirakawa, T.; Yodoi, J. Reactive oxygen-reducing and protein-refolding activities of adult T cell leukemia-derived factor/human thioredoxin. Biochem. Biophys. Res. Commun. 1992, 186, 1220-1226.
30. Wood, Z.A.; Schroder, E.; Robin Harris, J.; Poole, L.B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 2003, 28, 32-40.
31. Rhee, S.G.; Chae, H.Z.; Kim, K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic. Biol. Med. 2005, 38, 1543-1552.
32. Immenschuh, S.; Baumgart-Vogt, E. Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid. Redox Signal. 2005, 7, 768-777.
33. Chae, H.Z.; Kim, H.J.; Kang, S.W.; Rhee, S.G. Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes Res. Clin. Pract. 1999, 45, 101-112.
34. Bertini, R.; Howard, O.M.; Dong, H.F.; Oppenheim, J.J.; Bizzarri, C.; Sergi, R.; Caselli, G.; Pagliei, S.; Romines, B.; Wilshire, J.A.; Mengozzi, M.; Nakamura, H.; Yodoi, J.; Pekkari, K.; Gurunath, R.; Holmgren, A.; Herzenberg, L.A.; Ghezzi, P. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J. Exp. Med. 1999, 189, 1783-1789.
35. Kondo, N.; Nakamura, H.; Masutani, H.; Yodoi, J. Redox regulation of human thioredoxin network. Antioxid. Redox. Signal. 2006, 8, 1881-1890.
36. Hirota, K.; Murata, M.; Sachi, Y.; Nakamura, H.; Takeuchi, J.; Mori, K.; Yodoi, J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J. Biol. Chem. 1999, 274, 27891-27897.
37. Demple, B.; Herman, T.; Chen, D.S. Cloning and expression of APE, the cDNA encoding the major human apurinic endonuclease: definition of a family of DNA repair enzymes. Proc. Natl. Acad. Sci. USA 1991, 88, 11450-11454.
38. Robson, C.N.; Hickson, I.D. Isolation of cDNA clones encoding a human apurinic/apyrimidinic endonuclease that corrects DNA repair and mutagenesis defects in E. coli xth (exonuclease III) mutants. Nucleic Acids Res. 1991, 19, 5519-5523.
39. Robson, C.N.; Milne, A.M.; Pappin, D.J.; Hickson, I.D. Isolation of cDNA clones encoding an enzyme from bovine cells that repairs oxidative DNA damage in vitro: homology with bacterial repair enzymes. Nucleic Acids Res. 1991, 19, 1087-1092.
40. Hirota, K.; Matsui, M.; Iwata, S.; Nishiyama, A.; Mori, K.; Yodoi, J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA 1997, 94, 3633-3638.
41. Wisdom, R. AP-1: one switch for many signals. Exp. Cell. Res. 1999, 253, 180-185.
42. Leppa, S.; Bohmann, D. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 1999, 18, 6158-6162.
43. Angel, P.; Karin, M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1991, 1072, 129-157.
44. Abate, C.; Patel, L.; Rauscher, F.J., 3rd; Curran, T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 1990, 249, 1157-1161.
45. Ema, M.; Hirota, K.; Mimura, J.; Abe, H.; Yodoi, J.; Sogawa, K.; Poellinger, L.; Fujii-Kuriyama, Y. Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. 1999, 18, 1905-1914.
46. Otaki, M.; Hatano, M.; Kobayashi, K.; Ogasawara, T.; Kuriyama, T.; Tokuhisa, T. Cell cycle-dependent regulation of TIAP/m-survivin expression. Biochim. Biophys. Acta 2000, 1493, 188-194.
47. Stehlik, C.; de Martin, R.; Kumabashiri, I.; Schmid, J.A.; Binder, B.R.; Lipp, J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J. Exp. Med. 1998, 188, 211-216.
48. Wang, C.Y.; Mayo, M.W.; Korneluk, R.G.; Goeddel, D.V.; Baldwin, A.S., Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281, 1680-1683.
49. Matthews, J.R.; Wakasugi, N.; Virelizier, J.L.; Yodoi, J.; Hay, R.T. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res. 1992, 20, 3821-3830.
50. Saitoh, M.; Nishitoh, H.; Fujii, M.; Takeda, K.; Tobiume, K.; Sawada, Y.; Kawabata, M.; Miyazono, K.; Ichijo, H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998, 17, 2596-2606.
51. Wei, S.J.; Botero, A.; Hirota, K.; Bradbury, C.M.; Markovina, S.; Laszlo, A.; Spitz, D.R.; Goswami, P.C.; Yodoi, J.; Gius, D. Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer Res. 2000, 60, 6688-6695.
52. Tanaka, T.; Nishiyama, Y.; Okada, K.; Hirota, K.; Matsui, M.; Yodoi, J.; Hiai, H.; Toyokuni, S. Induction and nuclear translocation of thioredoxin by oxidative damage in the mouse kidney: independence of tubular necrosis and sulfhydryl depletion. Lab. Invest. 1997, 77, 145-155.
53. Holmgren, A. Thioredoxin. Annu. Rev. Biochem. 1985, 54, 237-271.
54. Osborne, S.A.; Hawkes, H.J.; Baldwin, B.L.; Alexander, K.A.; Svingen, T.; Clarke, F.M.; Tonissen, K.F. The tert-butylhydroquinone-mediated activation of the human thioredoxin gene reveals a novel promoter structure. Biochem. J. 2006, 398, 269-277.
55. Kim, Y.C.; Masutani, H.; Yamaguchi, Y.; Itoh, K.; Yamamoto, M.; Yodoi, J. Hemin-induced activation of the thioredoxin gene by Nrf2. A differential regulation of the antioxidant responsive element by a switch of its binding factors. J. Biol. Chem. 2001, 276, 18399-18406.
56. Rundlof, A.K.; Carlsten, M.; Arner, E.S. The core promoter of human thioredoxin reductase 1: cloning, transcriptional activity, and Oct-1, Sp1, and Sp3 binding reveal a housekeeping-type promoter for the AU-rich element-regulated gene. J. Biol. Chem. 2001, 276, 30542-30551.
57. Rundlof, A.K.; Janard, M.; Miranda-Vizuete, A.; Arner, E.S. Evidence for intriguingly complex transcription of human thioredoxin reductase 1. Free Radic. Biol. Med. 2004, 36, 641-656.
58. Hintze, K.J.; Wald, K.A.; Zeng, H.; Jeffery, E.H.; Finley, J.W. Thioredoxin reductase in human hepatoma cells is transcriptionally regulated by sulforaphane and other electrophiles via an antioxidant response element. J. Nutr. 2003, 133, 2721-2727.
59. Takagi, Y.; Mitsui, A.; Nishiyama, A.; Nozaki, K.; Sono, H.; Gon, Y.; Hashimoto, N.; Yodoi, J. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc. Natl. Acad. Sci. USA 1999, 96, 4131-4136.
60. Ramana, C.V.; Boldogh, I.; Izumi, T.; Mitra, S. Activation of apurinic/apyrimidinic endonuclease in human cells by reactive oxygen species and its correlation with their adaptive response to genotoxicity of free radicals. Proc. Natl. Acad. Sci. USA 1998, 95, 5061-5066.
61. Yao, K.S.; Xanthoudakis, S.; Curran, T.; O'Dwyer, P.J. Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol. Cell. Biol. 1994, 14, 5997-6003.
62. Olinski, R.; Zastawny, T.; Budzbon, J.; Skokowski, J.; Zegarski, W.; Dizdaroglu, M. DNA base modifications in chromatin of human cancerous tissues. FEBS Lett. 1992, 309, 193-198.
63. Jaruga, P.; Zastawny, T.H.; Skokowski, J.; Dizdaroglu, M.; Olinski, R. Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Lett. 1994, 341, 59-64.
64. Szatrowski, T.P.; Nathan, C.F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991, 51, 794-798.
65. Morriss, G.M.; New, D.A. Effect of oxygen concentration on morphogenesis of cranial neural folds and neural crest in cultured rat embryos. J. Embryol. Exp. Morphol. 1979, 54, 17-35.
66. Kallio, P.J.; Wilson, W.J.; O'Brien, S.; Makino, Y.; Poellinger, L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J. Biol. Chem. 1999, 274, 6519-6525.
67. Huang, L.E.; Gu, J.; Schau, M.; Bunn, H.F. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 1998, 95, 7987-7992.
68. Salceda, S.; Caro, J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 1997, 272, 22642-22647.
69. Salceda, S.; Beck, I.; Srinivas, V.; Caro, J. Complex role of protein phosphorylation in gene activation by hypoxia. Kidney Int. 1997, 51, 556-559.
70. Li, F.; Sonveaux, P.; Rabbani, Z.N.; Liu, S.; Yan, B.; Huang, Q.; Vujaskovic, Z.; Dewhirst, M.W.; Li, C.Y. Regulation of HIF-1alpha stability through S-nitrosylation. Mol. Cell. 2007, 26, 63-74.
71. Chandel, N.S.; McClintock, D.S.; Feliciano, C.E.; Wood, T.M.; Melendez, J.A.; Rodriguez, A.M.; Schumacker, P.T. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J. Biol. Chem. 2000, 275, 25130-25138.
72. Mansfield, K.D.; Guzy, R.D.; Pan, Y.; Young, R.M.; Cash, T.P.; Schumacker, P.T.; Simon, M.C. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab. 2005, 1, 393-399.
73. Bell, E.L.; Klimova, T.A.; Eisenbart, J.; Moraes, C.T.; Murphy, M.P.; Budinger, G.R.; Chandel, N.S. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J. Cell. Biol. 2007, 177, 1029-1036.
74. Kietzmann, T.; Gorlach, A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Semin. Cell. Dev. Biol. 2005, 16, 474-486.
75. Guzy, R.D.; Hoyos, B.; Robin, E.; Chen, H.; Liu, L.; Mansfield, K.D.; Simon, M.C.; Hammerling, U.; Schumacker, P. T. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell. Metab. 2005, 1, 401-408.
76. Wang, G.L.; Jiang, B.H.; Semenza, G.L. Effect of altered redox states on expression and DNA-binding activity of hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. 1995, 212, 550-556.
77. Liu, Q.; Berchner-Pfannschmidt, U.; Moller, U.; Brecht, M.; Wotzlaw, C.; Acker, H.; Jungermann, K.; Kietzmann, T. A Fenton reaction at the endoplasmic reticulum is involved in the redox control of hypoxia-inducible gene expression. Proc. Natl. Acad. Sci. USA 2004, 101, 4302-4307.
78. Welsh, S.J.; Bellamy, W.T.; Briehl, M.M.; Powis, G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 2002, 62, 5089-5095.
79. Csiki, I.; Yanagisawa, K.; Haruki, N.; Nadaf, S.; Morrow, J.D.; Johnson, D.H.; Carbone, D.P. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res. 2006, 66, 143-150.
80. Jones, D.T.; Pugh, C.W.; Wigfield, S.; Stevens, M.F.; Harris, A.L. Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation. Clin. Cancer Res. 2006, 12, 5384-5394.
81. Berggren, M.; Gallegos, A.; Gasdaska, J.R.; Gasdaska, P.Y.; Warneke, J.; Powis, G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 1996, 16, 3459-3466.
82. Kim, H.J.; Chae, H.Z.; Kim, Y.J.; Kim, Y.H.; Hwangs, T.S.; Park, E.M.; Park, Y.M. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell. Biol. Toxicol. 2003, 19, 285-298.
83. Hedley, D.; Pintilie, M.; Woo, J.; Nicklee, T.; Morrison, A.; Birle, D.; Fyles, A.; Milosevic, M.; Hill, R. Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis. Am. J. Pathol. 2004, 164, 557-565.
84. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
85. Han, H.; Bearss, D.J.; Browne, L.W.; Calaluce, R.; Nagle, R.B.; Von Hoff, D.D. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 2002, 62, 2890-2896.
86. Raffel, J.; Bhattacharyya, A.K.; Gallegos, A.; Cui, H.; Einspahr, J.G.; Alberts, D.S.; Powis, G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J. Lab. Clin. Med. 2003, 142, 46-51.
87. Choi, J.H.; Kim, T.N.; Kim, S.; Baek, S.H.; Kim, J.H.; Lee, S.R.; Kim, J.R. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res. 2002, 22, 3331-3335.
88. Grogan, T.M.; Fenoglio-Prieser, C.; Zeheb, R.; Bellamy, W.; Frutiger, Y.; Vela, E.; Stemmerman, G.; Macdonald, J.; Richter, L.; Gallegos, A.; Powis, G. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum. Pathol. 2000, 31, 475-481.
89. Cha, M.K.; Suh, K.H.; Kim, I.H. Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J. Exp. Clin. Cancer. Res. 2009, 28, 93.
90. Gallegos, A.; Gasdaska, J.R.; Taylor, C.W.; Paine-Murrieta, G.D.; Goodman, D.; Gasdaska, P.Y.; Berggren, M.; Briehl, M.M.; Powis, G. Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res. 1996, 56, 5765-5770.
91. Lu, J.; Chew, E.H.; Holmgren, A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. U S A 2007, 104, 12288-12293.
92. Ceccarelli, J.; Delfino, L.; Zappia, E.; Castellani, P.; Borghi, M.; Ferrini, S.; Tosetti, F.; Rubartelli, A. The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. Int. J. Cancer 2008, 123, 1770-1778.
93. Farina, A.R.; Tacconelli, A.; Cappabianca, L.; Masciulli, M.P.; Holmgren, A.; Beckett, G.J.; Gulino, A.; Mackay, A.R. Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion. Eur. J. Biochem. 2001, 268, 405-413.
94. Lincoln, D.T.; Ali Emadi, E.M.; Tonissen, K.F.; Clarke, F.M. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 2003, 23, 2425-2433.
95. Chaiswing, L.; Bourdeau-Heller, J.M.; Zhong, W.; Oberley, T.D. Characterization of redox state of two human prostate carcinoma cell lines with different degrees of aggressiveness. Free Radic. Biol. Med. 2007, 43, 202-215.
96. Kim, S.J.; Miyoshi, Y.; Taguchi, T.; Tamaki, Y.; Nakamura, H.; Yodoi, J.; Kato, K.; Noguchi, S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin. Cancer Res. 2005, 11, 8425-8430.
97. Iwao-Koizumi, K.; Matoba, R.; Ueno, N.; Kim, S. J.; Ando, A.; Miyoshi, Y.; Maeda, E.; Noguchi, S.; Kato, K. Prediction of docetaxel response in human breast cancer by gene expression profiling. J. Clin. Oncol. 2005, 23, 422-431.
98. Sasada, T.; Iwata, S.; Sato, N.; Kitaoka, Y.; Hirota, K.; Nakamura, K.; Nishiyama, A.; Taniguchi, Y.; Takabayashi, A.; Yodoi, J. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J. Clin. Invest. 1996, 97, 2268-2276.
99. Marks, P.A. Thioredoxin in cancer--role of histone deacetylase inhibitors. Semin. Cancer Biol. 2006, 16, 436-443.
100. Yoshioka, J.; Schreiter, E.R.; Lee, R.T. Role of thioredoxin in cell growth through interactions with signaling molecules. Antioxid. Redox. Signal. 2006, 8, 2143-2151.
101. Butler, L.M.; Zhou, X.; Xu, W.S.; Scher, H.I.; Rifkind, R.A.; Marks, P.A.; Richon, V.M. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA 2002, 99, 11700-11705.
102. Powis, G.; Kirkpatrick, D.L. Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol. 2007, 7, 392-397.
103. Arner, E.S.; Holmgren, A. The thioredoxin system in cancer. Semin. Cancer Biol. 2006, 16, 420-426.
104. Mukherjee, A.; Martin, S.G. The thioredoxin system: a key target in tumour and endothelial cells. Br. J. Radiol. 2008, 81, s57-s68.
105. Tonissen, K.F.; Di Trapani, G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol. Nutr. Food Res. 2009, 53, 87-103.
106. Douer, D.; Tallman, M.S. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J. Clin. Oncol. 2005, 23, 2396-2410.
107. Gromer, S.; Arscott, L.D.; Williams, C.H., Jr.; Schirmer, R.H.; Becker, K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem. 1998, 273, 20096-20101.
108. Hashemy, S.I.; Holmgren, A. Regulation of the catalytic activity and structure of human thioredoxin 1 via oxidation and S-nitrosylation of cysteine residues. J. Biol. Chem. 2008, 283, 21890-21898.
109. Fang, J.; Holmgren, A. Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo. J. Am. Chem. Soc. 2006, 128, 1879-1885.
110. Wang, Y.; Zhang, H.; Holmgren, A.; Tian, W.; Zhong, L. Inhibitory effect of green tea extract and (-)-epigallocatechin-3-gallate on mammalian thioredoxin reductase and HeLa cell viability. Oncol. Rep. 2008, 20, 1479-1487.
111. Du, Y.; Wu, Y.; Cao, X.; Cui, W.; Zhang, H.; Tian, W.; Ji, M.; Holmgren, A.; Zhong, L. Inhibition of mammalian thioredoxin reductase by black tea and its constituents: implications for anticancer actions. Biochimie 2009, 91, 434-444.
112. Dewhirst, M.W.; Ong, E.T.; Braun, R.D.; Smith, B.; Klitzman, B.; Evans, S.M.; Wilson, D. Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia. Br. J. Cancer 1999, 79, 1717-1722.
113. Secomb, T.W.; Hsu, R.; Dewhirst, M.W.; Klitzman, B.; Gross, J.F. Analysis of oxygen transport to tumor tissue by microvascular networks. Int. J. Radiat. Oncol. Biol. Phys. 1993, 25, 481-489.
114. Dewhirst, M.W.; Kimura, H.; Rehmus, S.W.; Braun, R.D.; Papahadjopoulos, D.; Hong, K.; Secomb, T.W. Microvascular studies on the origins of perfusion-limited hypoxia. Br. J. Cancer Suppl. 1996, 27, S247-251.
115. Brown, J.M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br. J. Radiol. 1979, 52, 650-656.
116. Reinhold, H.S.; Blachiwiecz, B.; Blok, A. Oxygenation and reoxygenation in 'sandwich' tumours. Bibl. Anat. 1977, 270-272.
117. Yamaura, H.; Matsuzawa, T. Tumor regrowth after irradiation; an experimental approach. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 1979, 35, 201-219.
118. Lanzen, J.; Braun, R.D.; Klitzman, B.; Brizel, D.; Secomb, T.W.; Dewhirst, M.W. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res. 2006, 66, 2219-2223.
119. Nehmeh, S.A.; Lee, N.Y.; Schroder, H.; Squire, O.; Zanzonico, P.B.; Erdi, Y.E.; Greco, C.; Mageras, G.; Pham, H.S.; Larson, S.M.; Ling, C.C.; Humm, J. L. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70, 235-242.
120. Yuan, G.; Nanduri, J.; Bhasker, C.R.; Semenza, G.L.; Prabhakar, N.R. Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J. Biol. Chem. 2005, 280, 4321-4328.
121. Semenza, G.L.; Prabhakar, N.R. HIF-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia. Antioxid. Redox Signal. 2007, 9, 1391-1396.
122. Maulik, N.; Sato, M.; Price, B.D.; Das, D.K. An essential role of NFkappaB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS Lett. 1998, 429, 365-369.
123. Maulik, N.; Das, D.K. Potentiation of angiogenic response by ischemic and hypoxic preconditioning of the heart. J. Cell. Mol. Med. 2002, 6, 13-24.
124. Maulik, N.; Engelman, R.M.; Rousou, J.A.; Flack, J.E., 3rd; Deaton, D.; Das, D.K. Ischemic preconditioning reduces apoptosis by upregulating anti-death gene Bcl-2. Circulation 1999, 100, II369-375.
125. Maulik, N.; Goswami, S.; Galang, N.; Das, D.K. Differential regulation of Bcl-2, AP-1 and NF-kappaB on cardiomyocyte apoptosis during myocardial ischemic stress adaptation. FEBS Lett. 1999, 443, 331-336.
126. Maulik, N.; Sasaki, H.; Addya, S.; Das, D.K. Regulation of cardiomyocyte apoptosis by redox-sensitive transcription factors. FEBS Lett. 2000, 485, 7-12.
127. Das, D.K.; Engelman, R.M.; Kimura, Y. Molecular adaptation of cellular defences following preconditioning of the heart by repeated ischaemia. Cardiovasc. Res. 1993, 27, 578-584.
128. Flack, J.E., 3rd; Kimura, Y.; Engelman, R.M.; Rousou, J.A.; Iyengar, J.; Jones, R.; Das, D.K. Preconditioning the heart by repeated stunning improves myocardial salvage. Circulation 1991, 84, III369-374.
129. Li, G.C.; Vasquez, J.A.; Gallagher, K.P.; Lucchesi, B.R. Myocardial protection with preconditioning. Circulation 1990, 82, 609-619.
130. Murry, C.E.; Jennings, R.B.; Reimer, K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74, 1124-1136.
131. Yagi, K.; Liu, C.; Bando, T.; Yokomise, H.; Inui, K.; Hitomi, S.; Wada, H. Inhibition of reperfusion injury by human thioredoxin (adult T-cell leukemia-derived factor) in canine lung transplantation. J. Thorac. Cardiovasc. Surg. 1994, 108, 913-921.
132. Nakamura, H.; Vaage, J.; Valen, G.; Padilla, C.A.; Bjornstedt, M.; Holmgren, A. Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery. Free Radic. Biol. Med. 1998, 24, 1176-1186.
133. Kihlstrom, M. Protection effect of endurance training against reoxygenation-induced injuries in rat heart. J. Appl. Physiol. 1990, 68, 1672-1678.
134. Isowa, N.; Yoshimura, T.; Kosaka, S.; Liu, M.; Hitomi, S.; Yodoi, J.; Wada, H. Human thioredoxin attenuates hypoxia-reoxygenation injury of murine endothelial cells in a thiol-free condition. J. Cell. Physiol. 2000, 182, 33-40.
135. Turoczi, T.; Chang, V.W.; Engelman, R.M.; Maulik, N.; Ho, Y.S.; Das, D.K. Thioredoxin redox signaling in the ischemic heart: an insight with transgenic mice overexpressing Trx1. J. Mol. Cell. Cardiol. 2003, 35, 695-704.
136. Maulik, N.; Yoshida, T.; Engelman, R.M.; Deaton, D.; Flack, J.E., 3rd; Rousou, J.A.; Das, D.K. Ischemic preconditioning attenuates apoptotic cell death associated with ischemia/reperfusion. Mol. Cell. Biochem. 1998, 186, 139-145.
137. Gurusamy, N.; Malik, G.; Gorbunov, N.V.; Das, D.K. Redox activation of Ref-1 potentiates cell survival following myocardial ischemia reperfusion injury. Free Radic. Biol. Med. 2007, 43, 397-407.
138. Malik, G.; Gorbounov, N.; Das, S.; Gurusamy, N.; Otani, H.; Maulik, N.; Goswami, S.; Das, D.K. Ischemic preconditioning triggers nuclear translocation of thioredoxin and its interaction with Ref-1 potentiating a survival signal through the PI-3-kinase-Akt pathway. Antioxid. Redox. Signal. 2006, 8, 2101-2109.
139. Hawaleshka, A.; Jacobsohn, E. Ischaemic preconditioning: mechanisms and potential clinical applications. Can. J. Anaesth. 1998, 45, 670-682.
140. Zhu, Y.; Ohlemiller, K.K.; McMahan, B.K.; Gidday, J.M. Mouse models of retinal ischemic tolerance. Invest. Ophthalmol. Vis. Sci. 2002, 43, 1903-1911.
141. Zimmermann, C.; Ginis, I.; Furuya, K.; Klimanis, D.; Ruetzler, C.; Spatz, M.; Hallenbeck, J.M. Lipopolysaccharide-induced ischemic tolerance is associated with increased levels of ceramide in brain and in plasma. Brain Res. 2001, 895, 59-65.
142. Simon, R.P. Hypoxia versus ischemia. Neurology 1999, 52, 7-8.
143. Moolman, J.A.; Genade, S.; Winterbach, R.; Lochner, A. Preconditioning with hypoxia versus global ischemia in the isolated rat heart: effect on function and metabolism. Cardioscience 1994, 5, 73-80.
144. Gidday, J.M.; Fitzgibbons, J.C.; Shah, A.R.; Park, T.S. Neuroprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat. Neurosci. Lett. 1994, 168, 221-224.
145. Emerson, M.R.; Nelson, S.R.; Samson, F.E.; Pazdernik, T.L. A global hypoxia preconditioning model: neuroprotection against seizure-induced specific gravity changes (edema) and brain damage in rats. Brain Res. Protoc. 1999, 4, 360-366.
146. Gage, A.T.; Stanton, P.K. Hypoxia triggers neuroprotective alterations in hippocampal gene expression via a heme-containing sensor. Brain Res. 1996, 719, 172-178.
147. Barone, F.C.; White, R.F.; Spera, P.A.; Ellison, J.; Currie, R.W.; Wang, X.; Feuerstein, G.Z. Ischemic preconditioning and brain tolerance: temporal histological and functional outcomes, protein synthesis requirement, and interleukin-1 receptor antagonist and early gene expression. Stroke 1998, 29, 1937-1950; discussion 1950-1931.
148. Wick, A.; Wick, W.; Waltenberger, J.; Weller, M.; Dichgans, J.; Schulz, J.B. Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J. Neurosci. 2002, 22, 6401-6407.
149. Bernaudin, M.; Tang, Y.; Reilly, M.; Petit, E.; Sharp, F.R. Brain genomic response following hypoxia and re-oxygenation in the neonatal rat. Identification of genes that might contribute to hypoxia-induced ischemic tolerance. J. Biol. Chem. 2002, 277, 39728-39738.
150. Bernaudin, M.; Nedelec, A.S.; Divoux, D.; MacKenzie, E.T.; Petit, E.; Schumann-Bard, P. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J. Cereb. Blood Flow. Metab. 2002, 22, 393-403.